Skip to main content

Hormonal Assessment

Hormonal labs in the reconstructive practice serve a narrower role than in general andrology — but a sharper one. Testosterone deficiency directly affects penile-prosthesis satisfaction and post-radical-prostatectomy sexual rehabilitation, and is a routine reflex in the workup of erectile dysfunction, decreased libido, and pre-prosthetic counseling.[1][2] The same panel ordered for "low T workup" doubles as part of the preoperative evaluation before inflatable penile prosthesis or artificial urinary sphincter placement, since a baseline hematocrit and PSA are required before initiating testosterone replacement. Most importantly, PSA interpretation in our patient population is not the standard screening interpretation: men on 5-alpha-reductase inhibitors and trans women on gender-affirming estrogen require completely different reference frames, and missing this is the single most common error in this lab cluster.[3][4]

Testosterone & Gonadotropin Panel​

The AUA Testosterone Deficiency Guideline (2018, reaffirmed 2024) defines testosterone deficiency as a total testosterone <300 ng/dL measured on two separate morning, fasting blood draws, in a patient with consistent clinical symptoms.[1] A single low value is insufficient for diagnosis — diurnal variation alone can produce a 30–40% spread, and acute illness or sleep deprivation can transiently suppress levels.[5]

Indications in the Reconstructive Population​

ScenarioRationale
Erectile dysfunction (any etiology)Testosterone is part of the AUA-recommended initial ED workup; correction may improve PDE5i responsiveness
Post-radical prostatectomyTRT is not contraindicated in select men with biochemical-undetectable PSA after counseling
Post-radiation, post-pelvic-trauma, spinal-cord injuryHigher prevalence of secondary hypogonadism; affects rehabilitation goals
Pre-IPP counselingUntreated hypogonadism is associated with lower satisfaction; correction before or alongside IPP improves outcomes
Decreased libido / fatigue / loss of morning erectionsStandard symptom cluster for AUA evaluation

Conditions Warranting Testosterone Measurement Even Without Symptoms​

Per the AUA 2018 Testosterone Deficiency Guideline, several medical conditions independently justify a serum testosterone measurement even in the absence of classical hypogonadism symptoms, because their underlying pathophysiology overlaps so heavily with low T that detection materially changes management:[1]

  • Unexplained anemia
  • Bone-density loss / osteoporosis
  • Diabetes mellitus
  • Chemotherapy exposure
  • Testicular radiation
  • HIV / AIDS
  • Chronic narcotic / opioid use
  • Infertility
  • Pituitary dysfunction
  • Chronic corticosteroid use

This list matters disproportionately to the reconstructive practice. Many post-cystectomy, post-pelvic-trauma, post-pelvic-radiation, and spinal-cord-injury patients fall into multiple of these categories simultaneously — chronic opioids, anemia of chronic disease, post-radiation testicular dysfunction, and post-injury osteoporosis frequently co-cluster. Testosterone measurement in these patients is justified on the basis of comorbidity stacking alone, even when the patient does not volunteer libido or energy complaints.

Reflex Labs When Total T Is Low​

When total T returns <300 ng/dL on confirmatory testing, the next-step labs distinguish primary from secondary hypogonadism and identify treatable secondary causes:[1][5][6]

  • LH — elevated in primary (testicular) hypogonadism; low/normal in secondary (hypothalamic-pituitary)
  • FSH — adds infertility-axis information; elevated FSH with normal LH suggests Sertoli-cell dysfunction
  • Prolactin — order if LH is low/normal; prolactinoma is a treatable cause of secondary hypogonadism
  • Estradiol — order if gynecomastia is present or aromatase-inhibitor therapy is being considered
  • SHBG and free/calculated free testosterone — order when total T is borderline (250–400 ng/dL) and a condition that alters SHBG is present.[1] SHBG is decreased by obesity, type-2 diabetes, hypothyroidism, nephrotic syndrome, and exogenous androgens or glucocorticoids — these patients can have a falsely "normal" total T despite genuinely low bioavailable testosterone. SHBG is increased by aging, hyperthyroidism, hepatic disease/cirrhosis, HIV, and estrogen exposure — these patients can have a falsely low total T despite preserved bioavailable testosterone. In either scenario, free or calculated free testosterone is the more clinically faithful measurement.

Hematocrit — Baseline AND On-Therapy​

Hematocrit is the single most important safety parameter in TRT monitoring. Per AUA 2018:[1]

  • Baseline Hct >48% is a relative contraindication to TRT initiation — evaluate for sleep apnea, smoking, polycythemia vera before starting
  • On-therapy Hct >54% mandates dose reduction, switch of formulation (gels generate less erythrocytosis than injections), or therapeutic phlebotomy; persistent >54% requires discontinuation
  • Check at baseline, 3–6 months, and annually thereafter

The TRAVERSE trial (n=5,246, 2023 NEJM) reframed the cardiovascular conversation around TRT — confirming non-inferiority for major adverse cardiovascular events but identifying signals for atrial fibrillation, pulmonary embolism, and acute kidney injury that should be discussed in shared decision-making.[7]

PSA in the Reconstructive Practice​

The AUA/SUO 2023 Early Detection of Prostate Cancer guideline recommends shared decision-making for PSA screening in men ages 45–69 at average risk, with earlier initiation at age 40 for higher-risk groups: Black men, BRCA2 carriers, and men with strong family history of prostate, breast, ovarian, or pancreatic cancer.[3] NCCN aligns broadly, with risk-adapted intervals based on baseline PSA at age 45.[8]

When We Order PSA​

  • Pre-TRT baseline in men ≥40 — required by AUA 2018 before initiating testosterone therapy[1]
  • On-TRT surveillance — at 3–6 months, 12 months, then annually
  • Post-radical prostatectomy biochemical-recurrence surveillance — PSA is the primary tool; the threshold for biochemical recurrence is ≥0.2 ng/mL confirmed
  • Pre-prosthetic counseling in age-appropriate men — known prostate cancer status influences candidacy and counseling

Reconstruction-Specific Interpretation Caveats​

This is where standard reference ranges fail and the reconstructive surgeon must apply specialty-specific corrections.

5-Alpha-Reductase Inhibitors​

Finasteride and dutasteride reduce measured PSA by approximately 50% after ~12 months of therapy.[3][8] When interpreting PSA in a patient on a 5-ARI, the traditional teaching is to multiply the reported value by 2 to estimate the equivalent untreated PSA. A measured PSA of 2.0 ng/mL in a man on dutasteride for BPH/LUTS would, by this rule, represent a "true" PSA of ~4.0 ng/mL — a level that should prompt further evaluation. See 5-Alpha-Reductase Inhibitors for pharmacology.

The doubling rule is unreliable, however. A VA cohort study by Marks and colleagues found that only 35% of patients on 5-ARI demonstrated the expected 40–60% PSA decrease, while 30% had a >60% decrease — meaning a strict ×2 correction systematically under-estimates the true PSA in nearly a third of patients.[10] A more discriminating biopsy trigger is any increase from on-therapy nadir of ≥0.3 ng/mL, which has been proposed as a more accurate signal of clinically significant disease than rigid doubling.[10]

The clinical stakes of getting this wrong are substantial. In a large VA study by Sarkar and colleagues, failure to account for 5-ARI–induced PSA suppression was associated with longer time to diagnostic biopsy, higher Gleason grade at diagnosis, greater probability of nodal or metastatic disease at presentation, and higher prostate-cancer–specific mortality.[11] Failure to apply some form of correction is the most common cause of missed prostate-cancer diagnoses in patients on chronic 5-ARI therapy.

Gender-Affirming Estrogen Therapy​

In trans women on long-term feminizing hormone therapy, median PSA falls to ~0.02 ng/mL because androgen suppression dramatically reduces prostatic epithelial activity.[4] The standard general-population reference range (cutoff 4.0 ng/mL, age-adjusted thresholds) is not applicable. The Hall 2025 BJU International systematic review of PSA reference intervals in the gender-diverse population reinforces this: published values in trans women on estrogen-based GAH cluster well below cisgender male norms, and applying cisgender thresholds risks under-detection.[12]

Any detectable rise above the patient's own pre-estrogen baseline — or above ~0.1 ng/mL in a patient with no pre-treatment baseline — should prompt evaluation, not reassurance. Case reports compiled by Nik-Ahd and colleagues suggest that transgender women diagnosed with prostate cancer may present with more aggressive disease than cisgender controls, likely reflecting both the screening blind spot created by suppressed PSA values and delayed diagnosis.[4] The operational takeaway: clinicians should pay particular attention to rising PSA trends in this population, even when the absolute value remains within the standard "normal" range. Prostate-cancer screening in trans women must use the patient's own suppressed baseline as the reference frame. See Gender-Affirming Hormone Therapy.

Transient Elevations​

Several common factors transiently raise PSA and should be excluded before further workup:[3]

  • Recent ejaculation (within 48 hours) — defer collection
  • Prostatic instrumentation (DRE generally minor; cystoscopy, TURP, biopsy substantial) — defer 2–6 weeks depending on procedure
  • Acute prostatitis or symptomatic UTI — treat and retest in 4–6 weeks
  • Acute urinary retention — defer until catheter removed and voiding restored

Endocrine Evaluation in Male Infertility​

A brief acknowledgment: male-infertility evaluation overlaps with hormonal assessment but lives in a separate workflow.[9] When semen analysis returns abnormal, a hormonal panel including FSH, LH, total testosterone, and prolactin is standard. FSH is the most sensitive marker of spermatogenic failure — an elevated FSH with reduced sperm concentration suggests primary testicular failure, while a low FSH/LH/T pattern points to hypogonadotropic hypogonadism. Karyotype and Y-chromosome microdeletion testing are added when sperm concentration is <5 million/mL. The reconstructive surgeon's role here is usually to identify when infertility evaluation should run in parallel with the reconstructive workup (varicocele, post-vasectomy reversal, post-pelvic-trauma) and refer accordingly.

See Also​

References​

1. Mulhall JP, Trost LW, Brannigan RE, et al. "Evaluation and management of testosterone deficiency: AUA guideline." J Urol. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115

2. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004

3. Wei JT, Barocas D, Carlsson S, et al. "Early detection of prostate cancer: AUA/SUO guideline part I — prostate cancer screening." J Urol. 2023;210(1):46-53. doi:10.1097/JU.0000000000003491

4. Nik-Ahd F, Jarjour A, Figueiredo J, et al. "Prostate-specific antigen screening in transgender patients." Eur Urol. 2023;83(1):48-54. doi:10.1016/j.eururo.2022.09.007

5. Heidelbaugh JJ, Belakovskiy A. "Testosterone deficiency in adult men: evaluation and management." Am Fam Physician. 2024;109(6):543-549. https://www.aafp.org/pubs/afp/issues/2024/0600/testosterone-deficiency.html

6. De Silva NL, Grossmann M, Antonio L, et al. "Male hypogonadism: pathogenesis, diagnosis, and management." Lancet Diabetes Endocrinol. 2024;12(10):761-774. doi:10.1016/S2213-8587(24)00199-5

7. Lincoff AM, Bhasin S, Flevaris P, et al. "Cardiovascular safety of testosterone-replacement therapy (TRAVERSE)." N Engl J Med. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025

8. National Comprehensive Cancer Network. "NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection." Version 2.2026. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1460

9. Agarwal A, Baskaran S, Parekh N, et al. "Male infertility." Lancet. 2021;397(10271):319-333. doi:10.1016/S0140-6736(20)32667-2

10. Marks LS, Andriole GL, Fitzpatrick JM, et al. "The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations." J Urol. 2006;176(3):868-874. doi:10.1016/j.juro.2006.04.024

11. Sarkar RR, Parsons JK, Bryant AK, et al. "Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer." JAMA Intern Med. 2019;179(6):812-819. doi:10.1001/jamainternmed.2019.0280

12. Hall R, Wittert G, Grossmann M, et al. "Prostate-specific antigen reference intervals in the gender-diverse population: a systematic review." BJU Int. 2025. doi:10.1111/bju.16825